Having spent over 20 years working with customers in the life sciences industry, I’m well aware of the challenges medical device companies face when it comes to training surgeons. Almost all training is done in person, whether in the OR, clinic, or simulation center, which is not always the most efficient. And over time, these face-to-face meetings get extremely expensive.

You may not be thinking about the future scale-up to commercial production when you’re in the early stages of crafting a new biologic therapy. But it is prudent to keep your long-term production needs in mind.

CSL Behring and uniQure’s hemophilia B gene therapy etranacogene dezaparvovec hit its primary endpoint in an ASH late-breaker posted today.

Boston Scientific has retired its entire Lotus Edge heart valve program, effective immediately, leaving a gap in the company’s U.S. transcatheter aortic valve replacement offerings until a new model is approved by the FDA.

Following an upbeat release of top-line data earlier this year that showed its finerenone treatment helped stave off kidney and heart disease, Bayer is now providing more details on the drug’s ability to improve the health of chronic patients regardless of their past history of cardiovascular conditions.

Deep Genomics is wasting no time. Two weeks after hiring a new chief business officer to ramp up its partnering game, it’s unveiling its first biopharma tie-up: BioMarin. The duo will use the Toronto biotech’s artificial-intelligence-based drug discovery platform to discover new drugs for rare diseases.

Avrobio has shared data on the first Gaucher disease patient to receive its gene therapy AVR-RD-02. The patient, who was stable on enzyme replacement therapy at baseline, experienced a 22% drop in a toxic metabolite after receiving AVR-RD-02 and stopping taking the standard of care.

While a potentially dangerous irregular heartbeat may not be detected immediately after cardiac surgery, it may develop in the month to follow—further raising a person’s chances of stroke and making the case for wider use of remote digital monitoring.

IL-33 is a cytokine that’s known to have a dual role in the body: It can either dial up the immune response or turn it down. And it has been shown to be a key player in inflammatory diseases such as asthma and eczema as well as other conditions including obesity.

Diagnosing nonalcoholic steatohepatitis (NASH)—the excessive buildup of fats in the liver that can lead to liver cancer, failure and the need for a transplant—has always been a difficult prospect. Tissue biopsies may hit the wrong spot and miss the diffuse signs entirely, while imaging methods can be limited in effectiveness and may be subjective.